F-box protein 10, an NF-B-κdependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway

Cell Death and Differentiation

Volumn 18, Issue 7, 2011, Pages 1184-1195

  Ge, R ^a   Wang, Z ^a   Zeng, Q ^b   Xu, X ^b   Olumi, A F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

apoptosis; c FLIP; c Fos; FBXL10; NF B; TRAIL

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; F BOX PROTEIN; F BOX PROTEIN 10; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN C FOS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REGULATORY MECHANISM; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; F-BOX PROTEINS; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MICE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-FOS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR RELA; TRANSPLANTATION, HETEROLOGOUS;

EID: 79958797383     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.185     Document Type: Article

References (40)

1. Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007; 178: 1923-1930. (Pubitemid 46154665)
2. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67: 9425-9434. (Pubitemid 47535933)
3. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430. (Pubitemid 37328939)
4. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factorrelated apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004; 64: 7086-7091. (Pubitemid 39331021)
5. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-798.
6. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010; 29: 4752-4765.
7. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21: 3964-3973. (Pubitemid 32476458)
8. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247-3259. (Pubitemid 29043977)
9. Frescas D, Guardavaccaro D, Bassermann F, Koyama-Nasu R, Pagano M. JHDM1B/ FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature 2007; 450: 309-313. (Pubitemid 350100537)
10. Koyama-Nasu R, David G, Tanese N. The F-box protein Fbl10 is a novel transcriptional repressor of c-Jun. Nat Cell Biol 2007; 9: 1074-1080. (Pubitemid 47342313)
11. Asakuma J, Sumitomo M, Asano T, Asano T, Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 2003; 63: 1365-1370. (Pubitemid 36348718)
12. Shao R, Lee DF, Wen Y, Ding Y, Xia W, Ping B et al. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol Cancer Res 2005; 3: 219-226. (Pubitemid 40525332)
13. Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Bjorkstrand B et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 2008; 111: 4617-4626.
14. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 2007; 67: 2247-2255. (Pubitemid 46424244)
15. Zhang X, Huang X, Olumi AF. Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells. Int J Cancer 2009; 124: 1980-1989.
16. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462-1475. (Pubitemid 47031030)
17. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006; 5: 2251-2260. (Pubitemid 44530462)
18. Jin Z, McDonald III ER, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004; 279: 35829-35839. (Pubitemid 39100590)
19. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res 2004; 10: 8284-8292. (Pubitemid 40053388)
20. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281. (Pubitemid 34250106)
21. Stadel D, Mohr A, Ref C, Macfarlane M, Zhou S, Humphreys R et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010; 16: 5734-5749.
22. Choi H, Chang JW, Jung YK. Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase. Cell Death Differ 2010 (e-pub ahead of print 10 September 2010; doi:10.1038/cdd.2010.113).
23. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW et al. Sorafenib overcomes TRAIL resistance of Hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010; 16: 5189-5199.
24. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAILinduced death. Cancer Cell 2007; 12: 66-80. (Pubitemid 47001783)
25. Hurtado del Pozo C, Calvo RM, Vesperinas-Garcia G, Gomez-Ambrosi J, Fruhbeck G, Corripio-Sanchez R et al. IPO8 and FBXL10: new reference genes for gene expression studies in human adipose tissue. Obesity (Silver Spring) 2010; 18: 897-903.
26. He J, Kallin EM, Tsukada Y, Zhang Y. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). Nat Struct Mol Biol 2008; 15: 1169-1175.
27. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-2143. (Pubitemid 40516580)
28. Quan T, He T, Voorhees JJ, Fisher GJ. Ultraviolet irradiation induces Smad7 via induction of transcription factor AP-1 in human skin fibroblasts. J Biol Chem 2005; 280: 8079-8085. (Pubitemid 40349706)
29. Tanos T, Marinissen MJ, Leskow FC, Hochbaum D, Martinetto H, Gutkind JS et al. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J Biol Chem 2005; 280: 18842-18852. (Pubitemid 41379586)
30. Manchester KM, Heston WD, Donner DB. Tumour necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. Biochem J 1993; 290(Part 1): 185-190. (Pubitemid 23081218)
31. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L et al. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEKdependent pathway. J Biol Chem 2005; 280: 22856-22867. (Pubitemid 40853193)
32. Siegmund D, Mauri D, Peters N, Juo P, Thome M, Reichwein M et al. Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway. J Biol Chem 2001; 276: 32585-32590.
33. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004; 23: 2554-2558. (Pubitemid 38520752)
34. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003; 63: 1059-1066. (Pubitemid 36278439)
35. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3: 409-416. (Pubitemid 32288449)
36. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333-339. (Pubitemid 38987058)
37. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251: 146-157. (Pubitemid 46589773)
38. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-1737. (Pubitemid 29328217)
39. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005; 2: 607-614. (Pubitemid 41086852)
40. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinomaassociated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-5011. (Pubitemid 29472907)